• Japanese
  • Korean
  • Chinese
Cover Image

Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015

GlobalData's clinical trial report, "Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Irritable Bowel Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Irritable Bowel Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Irritable Bowel Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Irritable Bowel Syndrome
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Irritable Bowel Syndrome
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Irritable Bowel Syndrome Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Irritable Bowel Syndrome
      • Dec 18, 2014: Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
      • Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan
      • Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation
      • Oct 21, 2014: Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
      • Oct 21, 2014: Salix's TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea
      • Oct 17, 2014: Salix Pharmaceuticals Outlines Data of Rifaximin Presents at American College of Gastroenterology 2014 Annual Scientific Meeting
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Actavis plc
      • Clinical Trial Overview of Actavis plc
      • Astellas Pharma Inc.
      • Clinical Trial Overview of Astellas Pharma Inc.
      • Salix Pharmaceuticals Ltd.
      • Clinical Trial Overview of Salix Pharmaceuticals Ltd.
      • Ironwood Pharmaceuticals, Inc.
      • Clinical Trial Overview of Ironwood Pharmaceuticals, Inc.
      • AstraZeneca PLC
      • Clinical Trial Overview of AstraZeneca PLC
      • Ono Pharmaceutical Co., Ltd.
      • Clinical Trial Overview of Ono Pharmaceutical Co., Ltd.
      • Almirall, S.A.
      • Clinical Trial Overview of Almirall, S.A.
      • A. Menarini Industrie Farmaceutiche Riunite Srl
      • Clinical Trial Overview of A. Menarini Industrie Farmaceutiche Riunite Srl
    • Clinical Trial Overview of Top Institutes / Government
      • Mayo Clinic
      • Clinical Trial Overview of Mayo Clinic
      • University of North Carolina
      • Clinical Trial Overview of University of North Carolina
      • University of Nottingham
      • Clinical Trial Overview of University of Nottingham
      • Maastricht University Medical Center
      • Clinical Trial Overview of Maastricht University Medical Center
      • Sahlgrenska University Hospital
      • Clinical Trial Overview of Sahlgrenska University Hospital
      • Chinese University of Hong Kong
      • Clinical Trial Overview of Chinese University of Hong Kong
      • Cedars-Sinai Medical Center
      • Clinical Trial Overview of Cedars-Sinai Medical Center
      • Karolinska Institute
      • Clinical Trial Overview of Karolinska Institute
      • University of California, Los Angeles
      • Clinical Trial Overview of University of California, Los Angeles
      • Baylor College of Medicine
      • Clinical Trial Overview of Baylor College of Medicine
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Region, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries, 2015*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Suspended Clinical Trials, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Withdrawn Clinical Trials, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Terminated Clinical Trials, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Irritable Bowel Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Actavis plc, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Salix Pharmaceuticals Ltd., 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Ironwood Pharmaceuticals, Inc., 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Ono Pharmaceutical Co., Ltd., 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Almirall, S.A., 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by A. Menarini Industrie Farmaceutiche Riunite Srl, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by University of North Carolina, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Nottingham, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Maastricht University Medical Center, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Sahlgrenska University Hospital, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Chinese University of Hong Kong, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Cedars-Sinai Medical Center, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Karolinska Institute, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Baylor College of Medicine, 2015*

List of Figures

  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015*
  • Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E7 Countries (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Irritable Bowel Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015*
  • Irritable Bowel Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015*
  • GlobalData Methodology
Show More
Pricing
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top